NCT06807073Recruiting
Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps
Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal LSLs. The hypothesis is that performing complete defect closure following EMR of large colorectal LSLs will result in lower rates of adverse events compared to cases where no defect closure is performed. For participants with planned EMR, endoscopists will perform EMRs as per standard of care and: * prophylactic defect closure will either not be performed (control group), or will be performed (experimental group); * then, patients will be called between 14 and 44 days after EMR to assess for possible adverse events, and electronic medical files will be verified for emergency room visits and healthcare received for an adverse event; * finally, patients will undergo follow-up colonoscopy 6 months and 18 months after randomization.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 686 (estimated)
- First submitted
- 29 Jan 2025
- Start date
- 27 Feb 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Diseases
- Colorectal cancer
- NCT number
- NCT06807073
What you commit to
- Study type: Interventional
- Planned participants: 686
- From 27 Feb 2025 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- inflammatory bowel disease;
- overt signs of deep submucosal invasive cancer (JNET 3);
Lab values
- coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets \<50 x 109/L);
Other
- non-elective colonoscopy;
- poor general health (American Society of Anesthesiologists classification \>III);
- pedunculated polyps (Paris class Ip, Isp);
- appendiceal orifice or terminal ileum invasion;
- pregnancy.
Who the study is looking for
- adult ≥18 years old
- patients undergoing EMR for a large (≥20mm) colorectal LSL
- patients providing written and informed consent for study participation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier de l'Université de Montréal Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.